LNP023 Hydrochloride Form HB Crystallization for Stable Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing crystalline form of LNP023 hydrochloride, referred to as Form A, is less suitable for large-scale manufacturing due to its stability and physicochemical properties, necessitating a more stable form for reliable drug production.
Innovation Solution
A crystalline hydrate form of LNP023 hydrochloride, referred to as Form HB, is developed, exhibiting improved chemical and physical stability, hygroscopicity, solubility, dissolution, morphology, crystallinity, flowability, and wettability, making it suitable for large-scale manufacturing processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If crystalline Form A of LNP023 HCl is used, then the drug can be produced, but the stability and suitability for large-scale manufacturing is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the crystallization conditions (solvent system, temperature, pH) to transform the unstable Form A into the stable Form HB. This involves changing the physical and chemical parameters during the crystallization process to achieve a more stable polymorphic form with superior manufacturing properties.
Solution Approach 2:
The patent utilizes phase transitions by inducing a polymorphic transformation from Form A to Form HB through controlled crystallization. The process involves transitioning the material from one crystalline phase to another more stable phase, thereby improving both stability and manufacturability.
2Stability of the object's composition
If a more stable crystalline form is developed, then chemical and physical stability is improved, but the complexity of developing a new form increases
Solution Approach 1:
The patent applies self-service by allowing the crystalline material to spontaneously transform from Form A to the more stable Form HB under controlled crystallization conditions. The system self-organizes into the thermodynamically favored polymorphic form without requiring complex external intervention, thereby achieving stability improvement with manageable process complexity.
3Reliability
If polymorphic conversions are minimized, then reliable bioavailability and consistent efficacy are ensured, but the control of crystallization process becomes more difficult
Solution Approach 1:
The patent applies preliminary action by pre-establishing optimized crystallization parameters (solvent composition, temperature profile, pH control) that guide the formation of Form HB from the outset. By preparing the crystallization system in advance with the correct conditions, the process directly yields the desired stable polymorph without unwanted conversions, ensuring both reliability and manufacturability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Form HB ensures reliable bioavailability and consistent efficacy by minimizing polymorphic conversions during manufacturing and storage, ensuring stable drug product production.
Implementation Method 1
a crystalline form of LNP023 hydrochloride and to a process for its preparation
Implementation Method 2
Crystalline Form of LNP023 hydrochloride... Form HB... crystalline hydrate form
Data Source
AI summary
Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.